Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Clin Cancer Res. 2011 Feb 22;17(8):2328–2338. doi: 10.1158/1078-0432.CCR-10-2943

Table 1.

VEGF121/rGel and rGel cytotoxicity on MC3T3 cells and prostate cancer cell lines

Cell Line Cell Type Status IC50 (nM), VEGF121/rGel IC50 (nM), rGel
MC3T3 Mouse preosteoblast Log phase 30 100
MC3T3 Mouse preosteoblast Differentiated, 1 week 500 500
MC3T3 Mouse preosteoblast Differentiated, 2 weeks > 1000 > 1000
MC3T3 Mouse preosteoblast Differentiated, 3 weeks > 1000 > 1000
MDA PCa 2b Human Prostate Log phase 290 1150
C4-2B Human Prostate Log phase > 1000 > 1000
MDA PCa 118b Human Prostate Log phase > 1000 > 1000
PC-3 Human Prostate Log phase 225* 100*
*

Veenendaal et al.(25)